Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

被引：7
|
作者：
Li, Chenggong [1 ]
Wang, Xindi [1 ]
Wu, Zhuolin [1 ]
Luo, Wenjing [1 ]
Zhang, Yinqiang [1 ]
Kang, Yun [1 ]
Xu, Jia [1 ]
Huang, Zhongpei [1 ]
Du, Mengyi [1 ]
Tang, Lu [1 ]
Wu, Jianghua [1 ]
Liao, Danying [1 ]
Kou, Haiming [1 ]
Lu, Cong [1 ]
Jiang, Huiwen [1 ]
Wei, Qiuzhe [1 ]
Ke, Sha [1 ]
Zheng, Jing'e [1 ]
Xiong, Wei [2 ]
Deng, Jun [1 ]
Hu, Yu [1 ]
Mei, Heng [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China
[2] Wuhan Sian Med Technol Co Ltd, Wuhan, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4573 / 4574
页数：2
相关论文
共 50 条
  • [21] Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
    Sun, Fumou
    Cheng, Yan
    Wanchai, Visanu
    Guo, Wancheng
    Mery, David
    Xu, Hongwei
    Gai, Dongzheng
    Siegel, Eric
    Bailey, Clyde
    Ashby, Cody
    Al Hadidi, Samer
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Ma, Yupo
    Yi, Qing
    Orlowski, Robert Z.
    Zangari, Maurizio
    van Rhee, Frits
    Janz, Siegfried
    Bishop, Gail
    Tricot, Guido
    Shaughnessy, John D.
    Zhan, Fenghuang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [22] Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
    Fumou Sun
    Yan Cheng
    Visanu Wanchai
    Wancheng Guo
    David Mery
    Hongwei Xu
    Dongzheng Gai
    Eric Siegel
    Clyde Bailey
    Cody Ashby
    Samer Al Hadidi
    Carolina Schinke
    Sharmilan Thanendrarajan
    Yupo Ma
    Qing Yi
    Robert Z. Orlowski
    Maurizio Zangari
    Frits van Rhee
    Siegfried Janz
    Gail Bishop
    Guido Tricot
    John D. Shaughnessy
    Fenghuang Zhan
    Nature Communications, 15
  • [23] Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed/refractory multiple myeloma
    Reyes, Kevin
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy
    Wolf, Jeffrey
    Arora, Shagun
    Chung, Alfred
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S31 - S32
  • [24] A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
    Li, Chenggong
    Mei, Heng
    Hu, Yu
    Guo, Tao
    Liu, Lin
    Jiang, Huiwen
    Tang, Lu
    Wu, Yaohui
    Ai, Lisha
    Deng, Jun
    Jin, Dan
    BLOOD, 2019, 134
  • [25] High Activation of BCMA CAR-T Cells Contributes to Increased Response Rate for Patients With Relapsed/Refractory Multiple Myeloma
    Hu, Yongxian
    Zhao, Houli
    Chang, Alex Hongsheng
    Nagler, Arnon
    Huang, He
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 51 - 51
  • [26] Safety and Efficacy of Anti-Bcma CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Literature
    Khan, Israr
    Rafae, Abdul
    Javaid, Anum
    Ahmed, Zahoor
    Qadeer, Haifza Abeera
    Khan, Sana Irfan
    Dar, Abdul Jabbar
    Khurshid, Qasim
    Jaan, Ali
    Khalid, Farhan
    Aijaz, Zobia
    Hashmi, Mydah Sajid
    Malik, Mustafa Nadeem
    Anwer, Faiz
    BLOOD, 2020, 136
  • [27] BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
    Yan, Yuhan
    Tu, Yixuan
    Cheng, Qian
    Zhang, Jian
    Wang, Erhua
    Deng, Zuqun
    Yu, Yan
    Wang, Liwen
    Liu, Rui
    Chu, Ling
    Kang, Liqing
    Liu, Jing
    Li, Xin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [28] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
  • [29] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [30] A Phase 1 Study of P-BCMA-ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
    Dholaria, Bhagirathbhai
    Kocoglu, Mehmet
    Andrew, Kin
    Ramakrishnan, Aravind
    Shune, Leyla
    Ganguly, Siddhartha
    Cruz, Jose
    Strouse, Christopher
    Malek, Ehsan
    Faber, Edward
    McArthur, Katherine
    McCaigue, Joanne
    DePrimo, Sam
    Martin, Chris
    Haag, Sabrina
    Eskew, Jeff
    Namini, Hamid
    Christie, Ellen
    Belani, Rajesh
    Rizvi, Syed
    Cranert, Stacey
    Coronella, Julia
    Shedlock, Devon
    Costello, Caitlin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S3 - S3
12345